Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

Bevacizumab (Avastin™; rhuMab VEGF), a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), significantly prolongs survival when added to intravenous 5‐fluorouracil‐based chemotherapy in first‐line metastatic colorectal cancer (CRC) treatment. Because antiangiogenic agents might inhibit wound healing, we assessed postoperative wound healing complications in two randomized trials of 5 mg/kg bevacizumab in CRC treatment.

[1]  J. Hecht,et al.  Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[3]  I. B. Rinkes,et al.  Surgery and angiogenesis. , 2004 .

[4]  C. Rödel,et al.  Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO‐94 , 2003, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[5]  Bruce Klitzman,et al.  Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  Andreas Friedl,et al.  Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Napoleone Ferrara,et al.  Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. , 2002, Seminars in oncology.

[8]  I. B. Borel Rinkes,et al.  Adverse effects of the antiangiogenic agent angiostatin on the healing of experimental colonic anastomoses , 2002, Annals of Surgical Oncology.

[9]  C. V. D. van de Velde,et al.  Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Detmar,et al.  The angiogenesis inhibitor vasostatin does not impair wound healing at tumor-inhibiting doses. , 2001, The Journal of investigative dermatology.

[11]  G. Wilding,et al.  Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  R. Timpl,et al.  The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  M. Detmar,et al.  Thrombospondin‐1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice , 2000, The EMBO journal.

[14]  A. Feldman,et al.  The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. , 2000, The Journal of surgical research.

[15]  D. García-Olmo,et al.  Effects of Perioperative Treatment with TNP-470 on the Resistance of Colonic Anastomoses in Rats , 2000, Digestive Surgery.

[16]  G. Hubens,et al.  Experimental study of intraperitoneal suramin on the healing of colonic anastomoses , 1999, The British journal of surgery.

[17]  G. Anderson,et al.  Angiogenesis inhibitor TNP-470 inhibits murine cutaneous wound healing. , 1999, The Journal of surgical research.

[18]  M. Carlson,et al.  Acute wound failure. , 1997, The Surgical clinics of North America.

[19]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[20]  N. Kemeny,et al.  Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H. Taniguchi,et al.  Angiogenesis inhibitor TNP‐470 prevents implanted liver metastases after partial hepatectomy in an experimental model without impairing wound healing , 1996, The British journal of surgery.

[22]  O. Søreide,et al.  Burst abdomen and incisional hernia after major gastrointestinal operations--comparison of three closure techniques. , 1995, The European journal of surgery = Acta chirurgica.

[23]  Kishor S. Trivedi,et al.  A COMPARISON OF APPROXIMATE INTERVAL ESTIMATORS FOR THE BERNOULLI PARAMETER , 1993 .

[24]  R. Buller,et al.  Effects of early postoperative chemotherapy on wound healing , 1992, Obstetrics and gynecology.

[25]  D. Collett.  Modelling Binary Data , 1991 .

[26]  N. Petrelli,et al.  The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.